Literature DB >> 21953789

Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease.

Alberto J Espay1, Joe P Giuffrida, Robert Chen, Megan Payne, Filomena Mazzella, Emily Dunn, Jennifer E Vaughan, Andrew P Duker, Alok Sahay, Sang Jin Kim, Fredy J Revilla, Dustin A Heldman.   

Abstract

Although movement impairment in Parkinson's disease includes slowness (bradykinesia), decreased amplitude (hypokinesia), and dysrhythmia, clinicians are instructed to rate them in a combined 0-4 severity scale using the Unified Parkinson's Disease Rating Scale motor subscale. The objective was to evaluate whether bradykinesia, hypokinesia, and dysrhythmia are associated with differential motor impairment and response to dopaminergic medications in patients with Parkinson's disease. Eighty five Parkinson's disease patients performed finger-tapping (item 23), hand-grasping (item 24), and pronation-supination (item 25) tasks OFF and ON medication while wearing motion sensors on the most affected hand. Speed, amplitude, and rhythm were rated using the Modified Bradykinesia Rating Scale. Quantitative variables representing speed (root mean square angular velocity), amplitude (excursion angle), and rhythm (coefficient of variation) were extracted from kinematic data. Fatigue was measured as decrements in speed and amplitude during the last 5 seconds compared with the first 5 seconds of movement. Amplitude impairments were worse and more prevalent than speed or rhythm impairments across all tasks (P < .001); however, in the ON state, speed scores improved exclusively by clinical (P < 10(-6) ) and predominantly by quantitative (P < .05) measures. Motor scores from OFF to ON improved in subjects who were strictly bradykinetic (P < .01) and both bradykinetic and hypokinetic (P < 10(-6) ), but not in those strictly hypokinetic. Fatigue in speed and amplitude was not improved by medication. Hypokinesia is more prevalent than bradykinesia, but dopaminergic medications predominantly improve the latter. Parkinson's disease patients may show different degrees of impairment in these movement components, which deserve separate measurement in research studies. © 2011 Movement Disorder Society.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953789      PMCID: PMC3318914          DOI: 10.1002/mds.23893

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

1.  Research diagnostic criteria for Parkinson's disease.

Authors:  C D Ward; W R Gibb
Journal:  Adv Neurol       Date:  1990

Review 2.  Movement disorders associated with the serotonin selective reuptake inhibitors.

Authors:  R J Leo
Journal:  J Clin Psychiatry       Date:  1996-10       Impact factor: 4.384

3.  Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series.

Authors:  I H Richard; A Maughn; R Kurlan
Journal:  Mov Disord       Date:  1999-01       Impact factor: 10.338

4.  Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia.

Authors:  Asha Kishore; Alberto J Espay; Connie Marras; Thamer Al-Khairalla; Tamara Arenovich; Abena Asante; Janis Miyasaki; Anthony E Lang
Journal:  Mov Disord       Date:  2007-02-15       Impact factor: 10.338

Review 5.  Deep brain stimulation.

Authors:  Joel S Perlmutter; Jonathan W Mink
Journal:  Annu Rev Neurosci       Date:  2006       Impact factor: 12.449

6.  Parkinsonism exacerbated by paroxetine.

Authors:  F J Jiménez-Jiménez; J Tejeiro; G Martínez-Junquera; F Cabrera-Valdivia; J Alarcón; E García-Albea
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

7.  The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures.

Authors:  Dustin A Heldman; Joseph P Giuffrida; Robert Chen; Megan Payne; Filomena Mazzella; Andrew P Duker; Alok Sahay; Sang Jin Kim; Fredy J Revilla; Alberto J Espay
Journal:  Mov Disord       Date:  2011-04-29       Impact factor: 10.338

8.  The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa.

Authors:  Liborio Rampello; Santina Chiechio; Rocco Raffaele; Ignazio Vecchio; Francesco Nicoletti
Journal:  Clin Neuropharmacol       Date:  2002 Jan-Feb       Impact factor: 1.592

9.  Objective monitoring of tremor and bradykinesia during DBS surgery for Parkinson disease.

Authors:  S Papapetropoulos; J R Jagid; C Sengun; C Singer; B V Gallo
Journal:  Neurology       Date:  2008-04-08       Impact factor: 9.910

Review 10.  Deep brain stimulation in Parkinson's disease.

Authors:  Kelly E Lyons; Rajesh Pahwa
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

View more
  43 in total

1.  Comparing kinematic changes between a finger-tapping task and unconstrained finger flexion-extension task in patients with Parkinson's disease.

Authors:  W P Teo; J P Rodrigues; F L Mastaglia; G W Thickbroom
Journal:  Exp Brain Res       Date:  2013-05-18       Impact factor: 1.972

2.  Impact of regional striatal dopaminergic function on kinematic parameters of Parkinson's disease.

Authors:  Myung Jun Lee; Sha-Lom Kim; Chul Hyoung Lyoo; J O Rinne; Myung-Sik Lee
Journal:  J Neural Transm (Vienna)       Date:  2014-08-22       Impact factor: 3.575

3.  Altered premotor cortical oscillations during repetitive movement in persons with Parkinson's disease.

Authors:  Elizabeth L Stegemöller; David P Allen; Tanya Simuni; Colum D MacKinnon
Journal:  Behav Brain Res       Date:  2016-09-15       Impact factor: 3.332

4.  Feasibility of home-based automated Parkinson's disease motor assessment.

Authors:  Thomas O Mera; Dustin A Heldman; Alberto J Espay; Megan Payne; Joseph P Giuffrida
Journal:  J Neurosci Methods       Date:  2011-09-29       Impact factor: 2.390

5.  Motor cortical oscillations are abnormally suppressed during repetitive movement in patients with Parkinson's disease.

Authors:  Elizabeth L Stegemöller; David P Allen; Tanya Simuni; Colum D MacKinnon
Journal:  Clin Neurophysiol       Date:  2015-05-29       Impact factor: 3.708

6.  Continuous Assessment of Levodopa Response in Parkinson's Disease Using Wearable Motion Sensors.

Authors:  Christopher L Pulliam; Dustin A Heldman; Elizabeth B Brokaw; Thomas O Mera; Zoltan K Mari; Michelle A Burack
Journal:  IEEE Trans Biomed Eng       Date:  2017-04-25       Impact factor: 4.538

7.  Quantitative analysis of gait and balance response to deep brain stimulation in Parkinson's disease.

Authors:  Thomas O Mera; Danielle E Filipkowski; David E Riley; Christina M Whitney; Benjamin L Walter; Steven A Gunzler; Joseph P Giuffrida
Journal:  Gait Posture       Date:  2012-12-05       Impact factor: 2.840

Review 8.  Evolving concepts on bradykinesia.

Authors:  Matteo Bologna; Giulia Paparella; Alfonso Fasano; Mark Hallett; Alfredo Berardelli
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

9.  Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.

Authors:  Jan Rusz; Tereza Tykalová; Jiří Klempíř; Roman Čmejla; Evžen Růžička
Journal:  J Neural Transm (Vienna)       Date:  2016-02-03       Impact factor: 3.575

10.  Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease.

Authors:  Dustin A Heldman; Alberto J Espay; Peter A LeWitt; Joseph P Giuffrida
Journal:  Parkinsonism Relat Disord       Date:  2014-03-05       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.